Outcome of Different Therapeutic Interventions in Mild COVID-19 Patients in a Single OPD Clinic of West Bengal: A Retrospective study

Roy et al., medRxiv, doi:10.1101/2021.03.08.21252883, Mar 2021

Source

PDF

All
Studies

Meta
Analysis

https://c19ivm.org/roy.html

Ivermectin for COVID-19

4th treatment shown to reduce risk in August 2020, now with p < 0.00000000001 from 105 studies, recognized in 24 countries.

Lower risk for mortality, ventilation, ICU, hospitalization, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine treatments.

5,700+ studies for 145 treatments. c19ivm.org

Retrospective database analysis of 56 mild COVID-19 patients, all treated with vitamin C, vitamin D, and zinc, comparing ivermectin + doxycycline (n=14), AZ (n=13), HCQ (n=14), and SOC (n=15), finding that all groups recover quickly, and there was no significant difference between the groups. Subject to the usual limitation of a database study, very small size, and limited evaluation of patients.

This is the 43rd of 105 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 774 quintillion).

52 studies are RCTs, which show efficacy with p=0.00000021.

This study is excluded in the after exclusion results of meta analysis: no serious outcomes reported and fast recovery in treatment and control groups, there is little room for a treatment to improve results.

Important missing comments or errors? Let us know.

Study covers HCQ and ivermectin.

relative time to clinical response of wellbeing, 5.6% lower, relative time 0.94, p = 0.87, treatment 14, control 15, primary outcome.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Roy et al., 12 Mar 2021, retrospective, database analysis, India, preprint, 5 authors, dosage not specified, this trial uses multiple treatments in the treatment arm (combined with doxycycline) - results of individual treatments may vary.

This Paper Ivermectin All

Outcome of Different Therapeutic Interventions in Mild COVID-19 Patients in a Single OPD Clinic of West Bengal: A Retrospective study

Dr Sayak Roy, Shambo Samrat Samajdar, Santanu K Tripathi, Shatavisa Mukherjee, Kingshuk Bhattacharjee

doi:10.1101/2021.03.08.21252883

Introduction: With over 87,273,380 cases being reported and 1,899,440 deaths worldwide as of 9th January 2021, Coronavirus disease 2019 (COVID-19) has become the worst-hit pandemic till date. Every day clinicians are bombarded with many new treatment options that claim to be better than the others.

References

Ahmed, Karim, Ross, A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis

Ciccullo, Borghetti, Dal Verme, Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line, Int J Antimicrob Agents

Healthworld, COVID-19: Health Ministry issues revised home isolation guidelines

Janowitz, Gablenz, Pattinson, Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series, Gut

Liu, Cao, Xu, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov

Ncid, None

Oldenburg, Doan, Azithromycin for severe COVID-19, Lancet

Roy, Journey So Far With COVID 19 -A Comprehensive Review, European Journal Of Clinical And Experimental Medicine

Roy, Mainakmukhopadhyay, Ventricular arrhythmia risk based on ethnicity in COVID-19 patients on hydroxychloroquine and azithromycin combination: Viewpoint, SN Compr Clin Med

Ruan, Yang, Wang, Jiang, Song, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China, Intensive Care Med

Summary, Therapeutic management of patients with COVID-19

Velavan, Meyer, Mild versus severe COVID-19: Laboratory markers, Int J Infect Dis

Who, None

Wu, Liu, Yang, Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharm Sin B

Zamanian, Pollack, Jr, Gentile, Outpatient inhaled nitric oxide in a patient with vasoreactive idiopathic pulmonary arterial hypertension and COVID-19 infection, Am J Respir Crit Care Med

DOI record: { "DOI": "10.1101/2021.03.08.21252883", "URL": "http://dx.doi.org/10.1101/2021.03.08.21252883", "abstract": "AbstractIntroductionWith over 87,273,380 cases being reported and 1,899,440 deaths worldwide as of 9th January 2021, Coronavirus disease 2019 (COVID-19) has become the worst-hit pandemic till date. Every day clinicians are bombarded with many new treatment options that claim to be better than the others.Materials and methodsAfter screening the electronic database of COVID-19 patients retrospectively, 56 patients with mild COVID-19 infection matched the inclusion criteria and were divided into the four following groups - group having used Hydroxychloroquine (HCQ), group using doxycycline (DOX) + Ivermectin (IVR) combination, group receiving only azithromycin (AZ) and, group receiving only symptomatic treatment. The study’s primary objective was to see Clinical response of well-being (CRWB) reporting time after initiating treatment onset between the four different treatment arms.ResultsCRWB did not differ between the four groups receiving four different managements (p-value 0.846). There was significant correlation between blood levels of LDH (p-value 0.001), CRP (p-value 0.03) and D-dimer (p-value 0.04) with CRWB in IVR+DOX group and, between LDH (p-value 0.001), CRP (p-value 0.01) and age (p-value 0.035) with CRWB in the symptomatic management group.ConclusionMild COVID-19 infection in patients having low-risk to progress can be managed symptomatically without any specific drug intervention.", "accepted": { "date-parts": [ [ 2021, 3, 22 ] ] }, "author": [ { "ORCID": "http://orcid.org/0000-0002-6185-9375", "affiliation": [], "authenticated-orcid": false, "family": "Roy", "given": "Sayak", "sequence": "first" }, { "affiliation": [], "family": "Samajdar", "given": "Shambo Samrat", "sequence": "additional" }, { "affiliation": [], "family": "Tripathi", "given": "Santanu K", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0001-9524-1525", "affiliation": [], "authenticated-orcid": false, "family": "Mukherjee", "given": "Shatavisa", "sequence": "additional" }, { "affiliation": [], "family": "Bhattacharjee", "given": "Kingshuk", "sequence": "additional" } ], "container-title": [], "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2021, 3, 12 ] ], "date-time": "2021-03-12T14:40:23Z", "timestamp": 1615560023000 }, "deposited": { "date-parts": [ [ 2022, 12, 21 ] ], "date-time": "2022-12-21T09:03:55Z", "timestamp": 1671613435000 }, "group-title": "Infectious Diseases (except HIV/AIDS)", "indexed": { "date-parts": [ [ 2022, 12, 22 ] ], "date-time": "2022-12-22T05:31:07Z", "timestamp": 1671687067555 }, "institution": [ { "name": "medRxiv" } ], "is-referenced-by-count": 1, "issued": { "date-parts": [ [ 2021, 3, 12 ] ] }, "link": [ { "URL": "https://syndication.highwire.org/content/doi/10.1101/2021.03.08.21252883", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "246", "original-title": [], "posted": { "date-parts": [ [ 2021, 3, 12 ] ] }, "prefix": "10.1101", "published": { "date-parts": [ [ 2021, 3, 12 ] ] }, "publisher": "Cold Spring Harbor Laboratory", "reference": [ { "key": "2021032410001188000_2021.03.08.21252883v2.1", "unstructured": "Who.int. Accessed January 16, 2021. https://covid19.who.int/." }, { "key": "2021032410001188000_2021.03.08.21252883v2.2", "unstructured": "Executive Summary. Therapeutic management of patients with COVID-19. Nih.gov. Accessed January 16, 2021. https://files.covid19treatmentguidelines.nih.gov/guidelines/section/section_100.pdf" }, { "key": "2021032410001188000_2021.03.08.21252883v2.3", "unstructured": "Gov.in. Accessed January 16, 2021. https://www.wbhealth.gov.in/uploaded_files/corona/WB_Covid_protocol_book_25.09_.20_(1)_.pdf" }, { "key": "2021032410001188000_2021.03.08.21252883v2.4", "unstructured": "HealthWorld ET. COVID-19: Health Ministry issues revised home isolation guidelines. PTI. Published July 3, 2020. Accessed January 16, 2021. https://health.economictimes.indiatimes.com/news/policy/covid-19-health-ministry-issues-revised-home-isolation-guidelines/76767874" }, { "key": "2021032410001188000_2021.03.08.21252883v2.5", "unstructured": "Clinical management of COVID-19. Who.int. Accessed January 16, 2021. https://www.who.int/publications/i/item/clinical-management-of-covid-19" }, { "DOI": "10.1136/gutjnl-2020-321852", "doi-asserted-by": "publisher", "key": "2021032410001188000_2021.03.08.21252883v2.6" }, { "article-title": "A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness", "first-page": "214", "journal-title": "Int J Infect Dis", "key": "2021032410001188000_2021.03.08.21252883v2.7", "volume": "103", "year": "2020" }, { "DOI": "10.1164/rccm.202004-0937LE", "article-title": "Outpatient inhaled nitric oxide in a patient with vasoreactive idiopathic pulmonary arterial hypertension and COVID-19 infection", "doi-asserted-by": "crossref", "first-page": "130", "issue": "1", "journal-title": "Am J Respir Crit Care Med", "key": "2021032410001188000_2021.03.08.21252883v2.8", "volume": "202", "year": "2020" }, { "DOI": "10.1016/j.apsb.2020.02.008", "article-title": "Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods", "doi-asserted-by": "crossref", "first-page": "766", "issue": "5", "journal-title": "Acta Pharm Sin B", "key": "2021032410001188000_2021.03.08.21252883v2.9", "volume": "10", "year": "2020" }, { "article-title": "MainakMukhopadhyay. Ventricular arrhythmia risk based on ethnicity in COVID-19 patients on hydroxychloroquine and azithromycin combination: Viewpoint", "first-page": "1", "issue": "8", "journal-title": "SN Compr Clin Med", "key": "2021032410001188000_2021.03.08.21252883v2.10", "volume": "2", "year": "2020" }, { "DOI": "10.1016/S0140-6736(20)31863-8", "article-title": "Azithromycin for severe COVID-19", "doi-asserted-by": "crossref", "first-page": "936", "issue": "10256", "journal-title": "Lancet", "key": "2021032410001188000_2021.03.08.21252883v2.11", "volume": "396", "year": "2020" }, { "DOI": "10.1038/s41421-020-0156-0", "doi-asserted-by": "publisher", "key": "2021032410001188000_2021.03.08.21252883v2.12" }, { "key": "2021032410001188000_2021.03.08.21252883v2.13", "unstructured": "Ncid.sg. Accessed January 16, 2021. https://www.ncid.sg/Health-Professionals/Diseases-and-Conditions/Documents/Treatment%20Guidelines%20for%20COVID-19%20%282%20Apr%202020%29%20-final.pdf" }, { "key": "2021032410001188000_2021.03.08.21252883v2.14", "unstructured": "Therapeutic Management. Nih.gov. Accessed January 16, 2021. https://www.covid19treatmentguidelines.nih.gov/therapeutic-management/" }, { "DOI": "10.15584/ejcem.2020.4.7", "doi-asserted-by": "crossref", "key": "2021032410001188000_2021.03.08.21252883v2.15", "unstructured": "Roy, S. , 2020. Journey So Far With COVID 19 – A Comprehensive Review | European Journal Of Clinical And Experimental Medicine. [online] Ejcem.ur.edu.pl. Available at: <http://www.ejcem.ur.edu.pl/summary/journey-so-far-covid-19-comprehensive-review> [accessed 17 January 2021]. http://www.ejcem.ur.edu.pl/summary/journey-so-far-covid-19-comprehensive-review" }, { "key": "2021032410001188000_2021.03.08.21252883v2.16", "unstructured": "Prophylactic Ivermectin in COVID-19 Contacts. Clinicaltrials.gov. Accessed January 16, 2021. https://clinicaltrials.gov/ct2/show/results/NCT04422561." }, { "key": "2021032410001188000_2021.03.08.21252883v2.17", "unstructured": "USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19 - Study Results - ClinicalTrials.Gov. Clinicaltrials.gov. Accessed January 16, 2021. https://clinicaltrials.gov/ct2/show/results/NCT04425850." }, { "DOI": "10.1016/j.ijantimicag.2020.106017", "article-title": "Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line", "doi-asserted-by": "crossref", "first-page": "106017", "issue": "2", "journal-title": "Int J Antimicrob Agents", "key": "2021032410001188000_2021.03.08.21252883v2.18", "volume": "56", "year": "2020" }, { "DOI": "10.1016/j.ijid.2020.04.061", "doi-asserted-by": "publisher", "key": "2021032410001188000_2021.03.08.21252883v2.19" }, { "DOI": "10.1007/s00134-020-05991-x", "doi-asserted-by": "publisher", "key": "2021032410001188000_2021.03.08.21252883v2.20" } ], "reference-count": 20, "references-count": 20, "relation": {}, "resource": { "primary": { "URL": "http://medrxiv.org/lookup/doi/10.1101/2021.03.08.21252883" } }, "score": 1, "short-title": [], "source": "Crossref", "subtitle": [], "subtype": "preprint", "title": "Outcome of Different Therapeutic Interventions in Mild COVID-19 Patients in a Single OPD Clinic of West Bengal: A Retrospective study", "type": "posted-content" }

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0